|
US6372957B1
(en)
*
|
1998-11-10 |
2002-04-16 |
Board Of Regents, The University Of Texas System |
Transgenic mouse comprising a MEF2 binding site operatively linked to an indicator gene and methods of use
|
|
JP2001149081A
(ja)
*
|
1999-11-29 |
2001-06-05 |
Cyclex Co Ltd |
脱アセチル化酵素の活性測定方法、並びにこれら酵素の阻害剤もしくは促進剤のスクリーニング方法
|
|
PE20020354A1
(es)
*
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
|
US6706686B2
(en)
*
|
2001-09-27 |
2004-03-16 |
The Regents Of The University Of Colorado |
Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
|
|
US7154002B1
(en)
|
2002-10-08 |
2006-12-26 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
|
US20040077083A1
(en)
*
|
2002-10-17 |
2004-04-22 |
Isis Pharmaceuticals Inc. |
Antisense modulation of histone deacetylase 4 expression
|
|
US7250514B1
(en)
|
2002-10-21 |
2007-07-31 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
|
US20070104688A1
(en)
|
2003-02-13 |
2007-05-10 |
City Of Hope |
Small interfering RNA mediated transcriptional gene silencing in mammalian cells
|
|
US20040171118A1
(en)
*
|
2003-02-13 |
2004-09-02 |
City Of Hope |
Methods for directing DNA methylation in mammalian cells using homologous short double stranded RNAs
|
|
JP2006520796A
(ja)
|
2003-03-17 |
2006-09-14 |
タケダ サン ディエゴ インコーポレイテッド |
ヒストンデアセチラーゼインヒビター
|
|
EP1631268A2
(en)
*
|
2003-05-21 |
2006-03-08 |
Board Of Regents The University Of Texas System |
Inhibition of protein kinase c-mu (pkd) as a treatment for cardiac hypertrophy and heart failure
|
|
CA2535889A1
(en)
*
|
2003-08-29 |
2005-03-17 |
Aton Pharma, Inc. |
Combination methods of treating cancer
|
|
US20050159470A1
(en)
*
|
2003-12-19 |
2005-07-21 |
Syrrx, Inc. |
Histone deacetylase inhibitors
|
|
WO2005066151A2
(en)
*
|
2003-12-19 |
2005-07-21 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
|
CA2555632A1
(en)
*
|
2004-02-02 |
2005-08-18 |
Myogen, Inc. |
Inhibition of protein kinase c-related kinase (prk) as a treatment for cardiac hypertrophy and heart failure
|
|
US20050197336A1
(en)
*
|
2004-03-08 |
2005-09-08 |
Miikana Therapeutics Corporation |
Inhibitors of histone deacetylase
|
|
US7345043B2
(en)
*
|
2004-04-01 |
2008-03-18 |
Miikana Therapeutics |
Inhibitors of histone deacetylase
|
|
US20050288215A1
(en)
*
|
2004-04-05 |
2005-12-29 |
Mckinsey Timothy A |
Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure
|
|
CA2560334A1
(en)
|
2004-04-07 |
2005-10-20 |
Axiogenesis Ag |
Non-invasive, in vitro functional tissue assay systems
|
|
WO2005108598A1
(en)
|
2004-05-11 |
2005-11-17 |
Axiogenesis Ag |
Assay for drug discovery based on in vitro differentiated cells
|
|
FI20040675A0
(fi)
*
|
2004-05-12 |
2004-05-12 |
Orion Corp |
Menetelmä sydämen hypertrofian hoitoon ja estoon
|
|
US20060110390A1
(en)
*
|
2004-08-25 |
2006-05-25 |
Myogen, Inc. |
Inhibition of Ku as a treatment for cardiovascular diseases
|
|
WO2006060382A2
(en)
*
|
2004-11-30 |
2006-06-08 |
Trustees Of The University Of Pennsylvania |
Use of hdac and/or dnmt inhibitors for treatment of ischemic injury
|
|
WO2006066133A2
(en)
*
|
2004-12-16 |
2006-06-22 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
|
US7772245B2
(en)
|
2005-02-14 |
2010-08-10 |
Miikana Therapeutics, Inc. |
Inhibitors of histone deacetylase
|
|
US7604939B2
(en)
*
|
2005-03-01 |
2009-10-20 |
The Regents Of The University Of Michigan |
Methods of identifying active BRM expression-promoting HDAC inhibitors
|
|
US20100087328A1
(en)
*
|
2005-03-01 |
2010-04-08 |
The Regents Of The University Of Michigan |
Brm expression and related diagnostics
|
|
US7642253B2
(en)
*
|
2005-05-11 |
2010-01-05 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
|
US20070015777A1
(en)
*
|
2005-07-14 |
2007-01-18 |
Myogen, Inc. |
Use of Inhibitors of the Ubiquitin Proteasome Pathway as a Method of Increasing Contractility of the Heart
|
|
KR20080032188A
(ko)
*
|
2005-07-14 |
2008-04-14 |
다케다 샌디에고, 인코포레이티드 |
히스톤 탈아세틸화 효소 억제제
|
|
JP2009504656A
(ja)
*
|
2005-08-10 |
2009-02-05 |
ノバルティス アクチエンゲゼルシャフト |
デアセチラーゼ阻害剤の使用法
|
|
AU2006318652A1
(en)
*
|
2005-11-18 |
2007-05-31 |
Gloucester Pharmaceuticals, Inc. |
Metabolite derivatives of the HDAC inhibitor FK228
|
|
US7863414B2
(en)
|
2005-11-18 |
2011-01-04 |
The Board Of Regents Of The University Of Texas Systems |
Methods of treatment and uses for CaMKII and its interaction with HDACs and calpain
|
|
US20070207950A1
(en)
*
|
2005-12-21 |
2007-09-06 |
Duke University |
Methods and compositions for regulating HDAC6 activity
|
|
EP1976835A2
(en)
*
|
2006-01-13 |
2008-10-08 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
|
US20100226857A1
(en)
*
|
2006-03-29 |
2010-09-09 |
Jeannine Strobl |
Tumor cell differentiation agents as chemical inhibitors and treatments for intracellular parasites
|
|
EP2004234A2
(en)
*
|
2006-04-06 |
2008-12-24 |
Novartis AG |
Combination of organic compounds
|
|
EP2010476A4
(en)
|
2006-04-13 |
2011-01-26 |
Univ Wake Forest Health Sciences |
NITROXYL DISPENSERS FROM C-NITROSO COMPOUNDS
|
|
CA2649877A1
(en)
*
|
2006-04-24 |
2007-12-21 |
Gloucester Pharmaceuticals |
Gemcitabine combination therapy
|
|
WO2007146730A2
(en)
|
2006-06-08 |
2007-12-21 |
Gloucester Pharmaceuticals |
Deacetylase inhibitor therapy
|
|
JP2010514802A
(ja)
*
|
2006-12-29 |
2010-05-06 |
グラスター ファーマシューティカルズ， インコーポレイテッド |
ロミデプシンをベースとする癌の処置
|
|
JP2010514801A
(ja)
*
|
2006-12-29 |
2010-05-06 |
グラスター ファーマシューティカルズ， インコーポレイテッド |
ロミデプシンの精製
|
|
WO2008140708A1
(en)
*
|
2007-05-09 |
2008-11-20 |
The Trustees Of The University Of Pennsylvania |
Use of hdac inhibitors for treatment of cardiac rhythm disorders
|
|
US7737175B2
(en)
*
|
2007-06-01 |
2010-06-15 |
Duke University |
Methods and compositions for regulating HDAC4 activity
|
|
WO2009048540A1
(en)
*
|
2007-10-05 |
2009-04-16 |
U.S. Department Of Veterans Affairs Office Of General Counsel - Psg Iv (024) |
Method and composition for treating heart failure
|
|
WO2009089598A2
(en)
*
|
2008-01-18 |
2009-07-23 |
Katholieke Universiteit Leuven |
Msmb-gene methylation based diagnosis, staging and prognosis of prostate cancer
|
|
WO2010039697A2
(en)
*
|
2008-09-30 |
2010-04-08 |
Gilead Sciences, Inc. |
Selective inhibition of histone deacetylases 1 and 2 as a treatment for cardiac hypertrophy
|
|
US9512481B2
(en)
|
2009-09-11 |
2016-12-06 |
The Regents Of The University Of Colorado, A Body Corporate |
Polymorphisms in the PDE3A gene
|
|
CA2804795A1
(en)
|
2010-07-12 |
2012-01-19 |
Nicholas Vrolijk |
Romidepsin solid forms and uses thereof
|
|
US8859502B2
(en)
|
2010-09-13 |
2014-10-14 |
Celgene Corporation |
Therapy for MLL-rearranged leukemia
|
|
CN103347498B
(zh)
|
2010-10-13 |
2016-04-13 |
沙普药品公司 |
组蛋白脱乙酰酶抑制剂药物配方
|
|
AU2013202506B2
(en)
|
2012-09-07 |
2015-06-18 |
Celgene Corporation |
Resistance biomarkers for hdac inhibitors
|
|
AU2013202507B9
(en)
|
2012-11-14 |
2015-08-13 |
Celgene Corporation |
Inhibition of drug resistant cancer cells
|
|
NZ630311A
(en)
|
2013-12-27 |
2016-03-31 |
Celgene Corp |
Romidepsin formulations and uses thereof
|
|
TWI794171B
(zh)
|
2016-05-11 |
2023-03-01 |
美商滬亞生物國際有限公司 |
Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
|
|
TWI808055B
(zh)
|
2016-05-11 |
2023-07-11 |
美商滬亞生物國際有限公司 |
Hdac 抑制劑與 pd-1 抑制劑之組合治療
|
|
EP4037670A4
(en)
*
|
2019-10-03 |
2023-09-27 |
Tenaya Therapeutics, Inc. |
5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF
|
|
EP4076448A4
(en)
|
2019-12-20 |
2024-03-27 |
Tenaya Therapeutics, Inc. |
Fluoroalkyl-oxadiazoles and uses thereof
|
|
EP4333841A1
(en)
|
2021-05-04 |
2024-03-13 |
Tenaya Therapeutics, Inc. |
2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
|
|
CN116942822A
(zh)
*
|
2023-06-12 |
2023-10-27 |
深圳大学 |
Hdac2在治疗室性心律失常中的应用
|
|
CN118766882B
(zh)
*
|
2024-09-12 |
2025-02-21 |
北京大学第三医院（北京大学第三临床医学院） |
用于治疗心血管疾病的制剂及其应用和制备方法
|